|Articles|October 8, 2021
- Pharmaceutical Executive-10-01-2021
- Volume 41
- Issue 10
Pharmaceutical Executive, October 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Addressing Systemic Racism in Biopharmaover 4 years ago
Understanding the HCP: Patient-Level Data Proves Valuableover 4 years ago
Industry Game Changer: RWE Impacts on Drug Developmentover 4 years ago
Opposites Attractover 4 years ago
Defining the Chief Data Officerover 4 years ago
Leading Through Transitionover 4 years ago
Biotech Stocks Continue With Underperformanceover 4 years ago
Could Time Be the Next New Element in Pharma Revenue?over 4 years ago
Sharing the Science: Pharma’s Content Evolutionover 4 years ago
Data Science Calls for Shift in Executive Leadership MethodsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
3
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5